Skip to main content
PLOS One logoLink to PLOS One
. 2022 Sep 8;17(9):e0269219. doi: 10.1371/journal.pone.0269219

Effect of patient-delivered household contact tracing and prevention for tuberculosis: A household cluster-randomised trial in Malawi

Kruger Kaswaswa 1,2,*,#, Peter MacPherson 3,4,#, Moses Kumwenda 3, James Mpunga 2, Deus Thindwa 3, Marriott Nliwasa 1,3,5, Mphatso Mwapasa 1, Jon Odland 6, Tamiwe Tomoka 1, Geoffrey Chipungu 1, Mavuto Mukaka 4,7,, Elizabeth L Corbett 1,3,8,
Editor: Richard John Lessells9
PMCID: PMC9455850  PMID: 36074775

Abstract

Background

Household contact tracing provides TB screening and TB preventive therapy (TPT) to contacts at high risk of TB disease. However, it is resource intensive, inconvenient, and often poorly implemented. We investigated a novel model aiming to improve uptake.

Methods

Between May and December 2014, we randomised patient with TB who consented to participate in the trial to either standard of care (SOC) or intervention (PACTS) arms. Participants randomised to PACTS received one screening/triage tool (adapted from WHO integrated management of adolescent and adult illnesses [IMAI] guidelines) and sputum pots for each reported household contact. The tool guided participants through symptom screening; TPT (6-months of isoniazid) eligibility; and sputum collection for contacts. Patients randomised to SOC were managed in accordance with national guidelines, that is, they received verbal instruction on who to bring to clinics for investigation using national guidelines.

Main outcome and measures

The primary outcome was the proportion of adult contacts receiving treatment for TB within 3 months of randomisation. Secondary outcomes were the proportions of child contacts under age 5 years (U5Y) who were commenced on, and completed, TPT. Data were analyzed by logistic regression with random effects to adjust for household clustering.

Results

Two hundred and fourteen index TB participants were block-randomized from two sites (107 PACTS, reporting 418 contacts; and 107 SOC, reporting 420 contacts). Overall, 62.8% of index TB participants were HIV-positive and 52.1% were TB culture-positive. 250 otherwise eligible TB patients declined participation and 6 households (10 PACTS, 6 SOC) were lost to follow-up and were not included in the analysis. By three months, nine contacts (PACTS: 6, [1.4%]; SOC: 3, [0.7%]) had TB diagnosed, with no difference between groups (adjusted odds ratio [aOR]: 2.18, 95% CI: 0.60–7.95). Eligible PACTS contacts (37/96, 38.5%) were more likely to initiate TPT by 3-months compared to SOC contacts (27/101, 26.7%; aOR 2.27, 95% CI: 1.04–4.98). U5Y children in the PACTS arm (47/81 58.0%) were more likely to have initiated TPT before the 3-month visit compared to SOC children (36/89, 41.4%; aOR: 2.31, 95% CI: 1.05–5.06).

Conclusions and relevance

A household-centred patient-delivered symptom screen and IPT eligibility assessment significantly increased timely TPT uptake among U5Y children, but did not significantly increase TB diagnosis. This model needs to be optimized for acceptability, given low participation, and investigated in other low resource settings.

Clinical trial registration

TRIAL REGISTRATION NUMBER: ISRCTN81659509 https://www.isrctn.com/ISRCTN81659509?q=&filters=conditionCategory:Respiratory,recruitmentCountry:Malawi,ageRange:Mixed&sort=&offset=1&totalResults=1&page=1&pageSize=10&searchType=basic-search. 19 July 2012.

Introduction

An estimated 10 million people developed tuberculosis (TB) and 1.4 million died from the disease in 2019 [1]. TB is the most common presenting illness among people living with HIV, including those taking antiretroviral therapy (ART) and is the major cause of HIV-related deaths, globally [14]. Household contacts of adults with pulmonary TB are at risk of TB infection and subsequent active disease. Young children and HIV-positive people exposed through household contact are extremely vulnerable to TB infection and primary progressive TB disease, particularly when they have untreated HIV infection. The prevalence of active TB among household contacts is estimated to be 3.1% [5,6]. In rural South Africa, prevalence of TB in household contacts living with a known TB case was high compared to household contacts living in households without a known TB case (6,075 per 100,000 versus 407 per 100,000), with most contacts with culture-confirmed TB being asymptomatic [79]. The pooled yield of TB diagnosis in among children undergoing contact tracing investigations varies, with children younger than five years (8.5%) years being at higher risk than older age groups [10,11].

Systematic screening for TB–including household contact tracing–is likely to be more effective than passive case-finding alone both for individuals and for improving TB epidemiology [9,1214]. However, household contact tracing is challenging to implement, especially in low-resource settings [1518]. In Malawi, similar to other countries in the sub-Saharan African region, household contact tracing is recommended in national policy, but has been suboptimally implemented due to resource limitations (19). In routine practice in many settings, health workers advise index TB patients to bring their contacts to the health facility for symptom screening, followed by clinical investigations (sputum smear microscopy, chest radiography), if symptomatic [17,19,20]. Low update of facility-based household contact screening is likely to be explained by the high transport and opportunity costs associated with facility-based services and completing the screening process [19].

Interventions to increase uptake of TB screening and improve access to TB preventive therapy (TPT) among household contacts are urgently needed. Conventional models of facility-based or outreach services are highly acceptable but have limited capacity to scale-up to optimal levels. Alternatives models of health service delivery that make more use of households participation need to be explored to complement the shortfall of the conventional approaches. Alternative models such as “patient-delivered” strategies have potential to relieve patients of the financial costs that are associated with contact investigations done at facilities.

We therefore undertook a household cluster-randomised trial to investigate the effectiveness of a low-cost, patient-delivered household screening intervention, with the objective of detecting undiagnosed TB among close household contacts of TB patients and improving access to TPT. The main objective was to identify a potentially sustainable model that could be used as an alternative to facility-based contact tracing and screening to improve outcomes for household TB contacts.

Methods

Study design

An open label, parallel group cluster-randomised trial.

Study site and participants

Blantyre District is a major urban centre located in the Southern Province of Malawi and was home to an estimated 956,898 people in 2017 [21]. Adult HIV prevalence was 18.5%, and TB prevalence was estimated at 988 per 100,000 [22].

In Malawi, TB diagnosis, registration and treatment is provided by the National Tuberculosis Programme (NTP), with services available without charge at most hospitals and health centres. We selected as study clinics two health facilities in Blantyre (Queen Elizabeth Central Hospital, and Ndirande Health Centre) that recorded the greatest number of TB case notifications in the city in 2013 [NO_PRINTED_FORM].

Adults with pulmonary TB who registered for treatment at either site between 1st May 2014, and 30th December 2014 were screened for eligibility to be included in the trial. Inclusion criteria were: never previously having been treated for TB; aged 18 years or older on the day of TB registration; at least one child aged five years or younger residing in their households (this criteria removed in a subsequent protocol amendment); resident within Blantyre; and, if an in-patient, were likely to be discharged within two weeks. We excluded participants who were unwilling to provide informed consent, hospitalised patients unlikely to be discharged within 14 days (e.g. due to retreatment, transferred in and out of recruiting facility), and membership of a household already recruited into the study.

We defined a household to be a group of people who had lived in the same dwelling as the index case and who had shared meals or slept in the same room as the index case on most days of the preceding week. Participants completed a clinical and sociodemographic questionnaire and provided details of their current household members to Research Assistants.

Interventions: Standard of care

Participants allocated to the SOC group were provided with oral advice from study research assistants that they should encourage all household members to report to the health facility for TB screening and HIV testing in accordance with national guidelines. Participants were additionally advised to return to the facility after 28 days with their children. HIV testing and linkage to ART was offered to all index cases through the routine system.

Interventions: Patient-delivered household active case finding for TB (PACTS)

In addition to interventions received by the SOC group, in the intervention group (patient-delivered household active case finding for TB, PACTS) research assistants provided participants with verbal and written (in Chichewa) information and instructions on how to conduct a symptom screen for TB for all members of their households. Participants were given one TB screening checklist and “contact referral card” per household member, and asked that, upon their return to home, they conducted a TB symptom screen for each household member, recording demographic characteristics and the presence of cough of any duration, fever, weight loss, or night sweats. Participants were additionally provided with a supply of sputum cups, each with a prefilled laboratory request form and specimen bag. Using pictorial tools and verbal and written instructions, Research Assistants instructed participants to support adult (18 years or older) household members with any one or more of TB symptoms to produce a single sputum sample, with specific instruction about sputum collection in well-ventilated outdoor spaces.

Participants were asked to return to the study clinics at their subsequent planned routine TB treatment appointment (usually within 28 days), along with completed household contact screening cards and sputum samples from each symptomatic household member. We additionally asked that the participant bring all children under five years of age to this appointment for clinical assessment.

Clinic interventions: Both groups

At the study clinic, the trial physician identified all household contacts who returned to the clinic using study self-referral slips. Household contacts were assessed for the presence of TB symptoms by a study clinician without reference to allocation group and were offered HIV testing and TB testing including sputum smear microscopy, sputum Xpert MTB/Rif, and chest x-ray, if indicated, in accordance with Malawi national guidelines [20]. Sputum samples collected from household contacts at clinic assessment were transported to the TB Research Laboratory at the College of Medicine, University of Malawi, Blantyre for fluorescence microscopy and mycobacterial growth inhibitor tube (MGIT) culture, with laboratory staff blinded to allocation group. Household contacts with microbiologically-confirmed TB, or where the health worker made a clinical diagnosis of TB, were supported by research assistants to register for TB treatment at the same facility, with home tracing if required.

After assessment for contraindications, children with a negative TB symptom screen (and negative TB investigations, if done) were initiated onto 6-months of TPT (isoniazid preventive therapy, IPT), with dosing guided by the Malawi National TB Programme, with adherence counselling and monthly (or earlier if required) clinic appointments for follow-up through the routine National TB Programme.

Outcome assessment

All index case participants were contacted by telephone three months after recruitment, and an appointment was made for a household visit, with tracing supported using a previously validated electronic geolocation system [23]. During the household visit, all household members (including the index case) were interviewed and underwent a TB symptom screen if not taking TB treatment. Sputum samples for microscopy and MGIT culture were collected from adult household members with TB symptoms (any of cough, fever, weight loss, weight sweats), and both adults and children with TB symptoms were referred to the study clinic for assessment for TB treatment, including clinical assessment, sputum investigation and chest x-ray if required.

We additionally determined whether children aged five years or younger were taking IPT by inspecting medication bottles and patient carried treatment cards during the 3-month assessment. At the study clinics, household members with microbiologically confirmed or clinically-diagnosed TB were supported to access treatment, and children under 5 years in whom TB was excluded were initiated onto IPT. For all household contacts initiated onto IPT, we extracted data from the facility IPT registers for the subsequent 6-month treatment period.

Definitions and outcomes

We defined two primary trial outcomes. The first primary outcome was the proportion of household contacts with either microbiologically-confirmed or clinically-diagnosed TB at three months after recruitment of the index case participant. This analysis was limited to contacts not already taking TB treatment at the time of TB treatment registration by the index case. Microbiologically-confirmed TB was defined as: at least one positive sputum smear result, or at least one specimen culture-positive for M. tuberculosis. Clinically-diagnosed TB was defined through examination of patient-held medical records, with written clinical evidence that a decision to initiate anti-TB treatment had been made accepted, regardless of whether treatment had been started.

The second primary outcome was the proportion of household contacts aged five years or younger who initiated IPT between recruitment of the index case participant and the three-month outcome visit, excluding children reported to be taking IPT or TB treatment at baseline. IPT initiation was defined by documented evidence in clinical records, the study clinic IPT register, or in patient-carried treatment cards that a clinical decision to start IPT had been made, and that at least one month of IPT had been prescribed.

The secondary outcomes were: (i) the proportion of household contacts not taking TB treatment at baseline with microbiologically-confirmed TB diagnosed between recruitment of the index case and the three month outcome assessment; (ii) the proportion of household contacts not taking TB treatment at baseline who completed a TB symptom screen within three months; (iii) the proportion of household contacts not taking TB treatment at baseline with any TB symptoms at three month assessment; (iv) the proportion of household contacts not taking TB treatment at baseline with microbiologically-confirmed TB at three month assessment; and (v) the proportion of household contacts aged 5 years or younger and who initiated IPT who subsequently completed a six month course of IPT within 9-months, defined as having documented evidence of collecting at least six monthly supplies of IPT in the study clinic IPT register.

Randomisation and blinding

Index case participants and their households were randomised to either the PACTS or SOC group in a 1:1 ratio using block randomisation, with block size of four. Block randomisation codes were pre-generated by the study statistician using the uniform distribution function with a pre-defined seed set in Stata version 13.0. The block randomisation schedule was provided to a data manager independent of the trial and based at the central research offices. At each study clinic, once consent to participate was obtained, the recruiting research assistant would obtain a randomisation code and allocation group by telephoning the central data manager. Research assistants collecting trial outcomes were blinded to trial arm when conducting home visits, and investigator blinding was maintained until final analysis. No interim analysis was conducted.

Statistical methods

Our initial sample size was 424 households to provide 80% power to detect at least a 2.5-times relative difference in TB diagnosis, comparing between groups. This assumed a between cluster coefficient of variation of k = 0.30 [24,25], four household members per cluster, a cumulative incidence of active TB of 2% among household contacts allocated to the SOC group, and 20% loss-to-follow-up. As discussed in results, this sample size was not achieved due to the unanticipatedly high refusal to participate by otherwise eligible index patients.

We reported baseline characteristics of index case participants and their household contacts, stratified by allocated group. Outcomes were analysed by intention-to-treat, with all household members allocated to each group (excluding those reported to be taking TB treatment at time of index case recruitment) included in denominators [26]. For each outcome, we constructed a logistic regression model with a random-effects term to account for clustering between households to estimate odds ratios and 95% confidence intervals. In accordance with the protocol, as there was imbalance between groups in the proportion of households in the poorest quintiles and the education level of the household head, we additionally report multivariable odds ratios adjusted for these variables. We further analysed the second primary outcome using the time to event analysis method to investigate the delay in IPT initiation among children under 5 years old. We used the intervention arm as our reference groups to interpret the odds ratio during the analysis.

Ethical statement

The study was approved by the College of Medicine Research Ethics Committee (COMREC), University of Malawi (P.05/12/1210). Written (or independently witnessed thumbprint if illiterate) informed consent was obtained from all index TB cases. COMREC approved a waiver of consent for recruitment of household members. Prior to outcome assessment at the three-month household visit, we obtained written (or independently witnessed thumbprint) consent from all adult (18 year or older) household members, additional parental/guardian assessment for adolescents aged between 10 and 18 years, and parental/guardian consent for children aged 0–10 years. COMREC also granted a waiver of written informed consent/assent for children younger than 5 years initiating IPT, as this was “an international SOC” and national policy in Malawi. The authors confirm that all ongoing and related trials for this drug/intervention are registered. We delayed in registering the study before recruitment because collaborators wanted to identify a suitable acronym to be used for registration and finalise other administrative requirements for the study.

Results

Between May 1 and December 30, 2014, 742 index TB cases were assessed for eligibility, 464 met eligibility criteria, 214 were provided informed consent to participate and were randomly allocated to a trial group. One household in the PACTS group did not receive study interventions and was excluded from analysis (Fig 1). There were 849 household contacts that were reported by index cases at the time of recruitment. However, at the time of the evaluation 11 household contacts could not be traced. Thus, the 213 index TB cases had a total of 838 household contacts, 168 of whom were children aged under 5 years. A total of 418 household contacts in the PACTS group and 420 household contacts in the SOC group were analysed according to protocol in the intention-to-treat analysis.

Fig 1. Trial flow chart.

Fig 1

TB index case participants were predominantly male, and HIV-positivity just under 60% in both arms (Table 1). The median household size was five people, with 66% reporting having at least one child aged younger than five years of age, and a median of two children under five years of age per household. Other index case, household and contact details were balanced between groups, apart from sputum microbiology results (where index cases in the SOC arm were more likely to have microbiologically-confirmed disease than those in the PACTS arm), and household wealth quintile, where a smaller proportion of households in the PACTS group were in the poorest wealth quintile.

Table 1. Baseline characteristics of participants, household members and household contacts.

Characteristic PACTS: n (%) SOC: n (%)
TB patient characteristics
Participants 106 107
Men (%) 67 (63.2) 70 (65.4)
Age in years, median (range) 33.5 (19–73) 32.0 (18–70)
Marital Status, No (%)
    Living as if married 5(4.7) 5(4.7)
    Married 57(53.8) 61(57.0)
    Married but not living together 3 (2.8) 7 (6.5)
    Polygamous marriage 13 (12.3) 10 (9.3)
    Separated 4 (3.8) 0 (0.0)
    Single 7 (6.6) 5 (4.7)
    Widowed 17 (16.0) 19 (17.8)
Education (%)
     No school 3 (2.8) 4 (3.7)
     Primary 40 (37.7) 44 (41.1)
     Secondary 58 (54.7) 56 (52.3)
     Higher 5 (4.7) 3 (2.8)
Employed 69 (65.1) 77 (72.0)
HIV positivea 62 (59.6) 61(58.7)
ART treatedb 39 (54.2) 40 (57.1)
Sputum bacteriology*, c
    S+ve culture +ve 56 (52.8) 64 (59.8)
    S-ve culture +ve 50 (47.2) 43(40.2)
Household characteristics
Household size, median (range) 5 (2–19) 5 (0–11)
Children, median (range) 2 (0–7) 2 (0–8)
Has U5Y old, No. (%) 66 (62.3%) 66 (61.7%)
Age of household head in years, Median (range) 36.5 (21.0–80) 37.0 (18–77)
Household wealth quintiles**, d, No. (%)
    Poorest 15 (15.8) 24 (24.0)
    Poor than average 16 (16.8) 23 (23.0)
    Average poor 19 (20.0) 20 (20.0)
    Wealthier than average 22 (23.2) 17 (17.0)
    Least Poor 23 (24.2) 16 (16.0)
Previous TB history, No. (%)f 12 (12.5) 13 (12.9)
Household contacts characteristics
Contacts 418 420
Maleg 197 (47.2) 190 (45.2)
Female 220(52.8) 230 (54.8)
Age contact, median (range) 16.8(1–87) 13.0 (0–84)
Age-groups: contacts (years)
    0–5 81 (19.4) 87 (20.2)
Contact level of educatione
    No school 256 (61.8) 284 (67.6)
    Primary 75 (18.1) 76 (18.1)
    Secondary 68 (16.4) 50 (11.9)
    Higher 15 (3.6) 10 (2.4)

* Abbreviations: S+ve culture +ve = smear positive culture positive, S-ve culture +ve = smear negative culture positive, S-ve culture–ve = smear negative culture negative.

** Wealth score was derived from using the Malawi Proxy means tests from the 1997–98 Malawi Integrated Household Survey.

aMissing Values: PACTS:9, SOC:9.

bMissing Values: PACTS:34, SOC:37.

cMissing Values: PACTS:0, SOC:0.

dMissing Values: PACTS:11, SOC:7.

eMissing Values: PACTS:4, SOC:0.

fMissing Values: PACTS:10, SOC:6.

gMissing Values: PACTS:1, SOC:0.

In the PACTS group, 96/106 (90.6%) households and 418 household contacts were evaluated at three months. In the SOC group, 101/107 (94.4%) households and 420 household contacts were evaluated. Main reason for contacts not being evaluated was death, with six in the PACTS group and eight in SOC group.

Primary outcome 1: Tuberculosis diagnosis

Overall, a total of nine household contacts were diagnosed with TB during follow-up: three (0.7%) in the PACTS group and six (1.4%) in the SOC group (Table 2). There was no statistically significant difference in TB diagnosis between groups in unadjusted (OR: 2.02, 95% CI: 0.48–8.51) or adjusted comparisons (OR: 2.18, 95% CI: 0.60–7.95). Of these, 3.3% of households (7/214) had TB diagnosed before their home visit (3 PACTS, 4 SOC): unadjusted risk ratio (OR: 0.74, 95% CI: 0.17–3. 28) (Table 3).

Table 2. Effect of interventions on primary and secondary outcomes, at individual-level.

Outcome PACTS n/N (%) SOC n/N (%) Odds ratio 95% CI Adjusted odds ratio 95% CI
Primary outcomes
Proportion of household contacts diagnosed with TB 3/418 6/420 2.02 0.48–8.51 2.18 0.60–7.95
Proportion of under 5-year old household contacts who initiated IPT 47/81 36/87 2.02 0.96–4.24 1.79 0.80–4.02
Secondary outcomes
Proportion of under 5-year old household contacts who completed IPT within 9 months 39/81 30/87 1.76 0.90–3.44 1.31 0.61–2.85
Proportion of household contacts with symptoms of TB at 3-month assessment 46/418 66/420 0.66 0.39–1.12 0.66 0.39–1.10
Proportion of household contacts with microbiologically-confirmed TB at 3-month assessment 3/418
0.7 (0.1, 2.1)*
0/420
0 (0, 0.9)*
Proportion of households completing TB symptom screen by 3-month assessment by either: sputum or chest x-ray tests 20/96 10/101 2.39 1.06–5.43 2.58 1.12–5.97

*Binomial exact %(95% CI).Adjusted for clustering and wealth status. The reference group for the outcome is PACTS.

Table 3. Primary and secondary outcomes by trial arm, at household-level.

  Events: n/N Univariate logistic regression Multivariate logistic regression*
Outcomes PACTS SOC OR** 95% CI OR 95% CI
     
≥1TB case in household initiated before 3 month (10 outcome) 3/96 4/101 0.74 0.17–3.28 - -
≥1 under 5-year old child in household initiated IPT within 3 months in (10 outcome) 37/96 27/101 1.94 1.07–3.53 2.27 1.04–4.98
≥1 under 5-year old child in household completed IPT within 9 months 28/96 22/101 1.63 0.79–3.38 1.78 0.80–3.93
≥1 Contacts screened with sputum or X-rayed for TB before 3 months 20/96 10/101 2.39 1.05–5.44 - -

* = Multivariate: adjusted for difference between arms in wealth score and culture

** The reference group for the outcome is PACTS.

Primary outcome 2: IPT initiation among under five-year-old children

Using the numbers of U5Y children reported to be household contacts by index cases at recruitment, 47/81 (58.0%) in the PACTS had initiated IPT by three-month assessment. This compared to 36/87 children (41.4%) in the SOC group. In both unadjusted (OR: 2.02 95% CI: 0.96–4.24) and adjusted analysis (OR: 1.79, 95% CI: 0.80–4.02) there were no significant differences between groups (Table 2).

Secondary outcomes

Within the nine months following index case TB diagnosis, a total of 50 of 197 households with ≥1 contact aged ≤5years (25.4%) completed IPT at household level. Between the groups, there was no significant difference in the IPT completion between PACTS (28/96, 29.1%) and SOC (22/101, 21.7%; OR: 1.78; 95% CI: 0.80–3.93) arms. At individual level, a greater proportion of contacts completed IPT in the PACTS group (39/81, 48.1%) than the SOC group (30/87, 34.4%), but this difference was not significantly different (aOR, 1.31, 95% CI: 0.61–2.85) (Tables 2 and 3).

In the PACTS group, 11.0% (46/418) of household contacts had TB symptoms at 3 months compared to 15.7% (66/420) in the SOC group (aOR 0.66; 95%CI, 0.39–1.10). In the PACTs group 0.7% (3/418) household contacts had untreated microbiologically-confirmed TB compared to 0.0% (1/420) in the SOC group (aOR 2219.02, 95%CI, 7.10–6933.61).

Time to event of IPT initiation

In an unadjusted but not pre-set analysis, the mean time to IPT initiation was 1.55 months (95% CI: 36.6–54.9 days) in the PACTS arm while the mean time to initiating IPT was higher in the SOC (1.87 months (95% CI, 45.8–64.15). When adjusted for clustering, IPT initiation significantly favoured the PACTS arm (IRR: 1.67 (95% CI 1.07–2.62) (Fig 2).

Fig 2. Probability of not initiating IPT by 3 months after index diagnosis.

Fig 2

TB screening events and IPT eligibility assessments

After 7 months of providing screening and IPT eligibility assessment, 30 of 197 households (15.2%) had at least one household contact investigated by either sputum tests or chest X-ray. Of these, 20/96 (20.8%) were from PACTS group and 10/101 (9.9%) SOC, with the difference remaining significant after adjustment for clustering (aOR 2.58, 95%CI: 1.12–5.97—Table 2).

Discussion

In this study, we investigated the effectiveness of a low-cost patient-delivered household screening intervention. Although there was low cumulative burden of TB in both arms, evaluation of the patient-delivered approach showed that screening of household contacts has potential to improve the performance of household contact screening from the perspective of increasing the uptake of TB screening investigations (sputum examination and radiography) and initiation of TPT among children under five years of age, with reduced time to TPT initiation. However, this patient-centred approach did not increase detection of undiagnosed active TB or improve the completion rates of IPT among childhood household contacts.

To our knowledge, this is the first cluster randomised trial to investigate the effects of a patient-delivered screening and TPT assessment. Initiation of IPT during the first three months after diagnosing the index case was higher in the patient-delivered compared to the SOC at household level (38.5% versus 26.7% respectively). At individual level, IPT initiation significantly favoured patient-delivered compared to SOC (58.0% versus 41.4%). At a time when index TB patients may already be facing catastrophic costs due to accessing TB care, and so potentially reluctant to incur any additional costs, screening of contacts with chest X-ray or sputum examination was significantly increased under this patient-delivered approach. This suggests that index patients may have been more willing to invest in the health of their household members when symptomatic screening and IPT eligibility are conducted at home [29].

The yield of bacteriologically confirmed TB was lower in both arms (overall 0.4%, 3/838) than reported from South African studies, but within the expected range for bacteriologically confirmed TB in other African settings [27]. The overall prevalence of undiagnosed bacteriologically confirmed or active TB among the household contacts was 1.07% (9/838) compared to meta-analysis estimates of 1.4% (95% CI: 1.1–2.1) reported for low and middle-income countries [5].

To maximise the uptake of IPT, policy makers should be aware that uptake of IPT may increase further if there is promotion of HIV testing to TB contacts with explicit inclusion of PLHIV as IPT eligible within the Malawian NTP. When an index TB case is also a PLHIV, there is greater likelihood that people living in the same household are HIV-positive, and if so a great risk of developing active TB if HIV-positive [28]. Households with a TB patient who is HIV-positive will tend to yield more active TB among screened contacts especially in lower-income countries [29,30]. This supports the idea of including HIV testing for contacts and the need to screen household contacts of HIV-positive TB patients as a priority, to detect TB early and identify contacts who can benefit from IPT. Recommendations by WHO on TB contact screening have emphasized this [9,29]. The most recent Malawian recommendations include IPT for all PLHIV, and so IPT could be provided as part of HIV care for all contacts diagnosed HIV positive [20,28,29].

The analysis of time to initiate of IPT found that patient-delivered screening resulted in more rapid TPT initiation among U5Y, such that over 50% of children had initiated TPT by day 40. Therefore, patient-delivered screening likely reduces mean time to initiation of IPT. This supports findings from other studies investigating patient-delivered screening for contact tracing in sexually-transmitted diseases [31,32].

Our subgroup analysis found that willingness and ability to participate in patient-delivered screening and IPT initiation was closely associated with household wealth (S1 Table). However, National programmes should recognize that poverty remains one of the key determinants of health in Malawi, and globally. It plays a major role in many TB control activities. TB is related to poverty with association to poor living conditions, poor nutrition status and poor health services [3336]. We had anticipated that patient-delivered screening would be able to reach the poorest households but found that instead we introduced inequity. The reasons for this unanticipated finding need to be explored further. The intervention was highly utilized by those whose income was high which contrasted with the main aim of the intervention (S1 Table).

Limitations of this study includes the fact that we had a higher-than-expected refusal rate (51.7%) which limited study size and power of study. Thus, our participating households are not necessarily representative of all TB-affected households in Blantyre. We were not able to provide HIV testing and counselling to our household contacts, due to resource limitations. However, this would have provided estimates of HIV prevalence among household contacts and could also have increased TPT uptake in adults. Therefore, we cannot estimate HIV prevalence among TB contacts.

Potential contributions towards the lower-than-anticipated participation in this household level TB screening intervention include ill health of the index, and financial costs, and social stigma especially when a household visit is included. Lack of privacy within the Malawi National TB programme may exacerbate these concerns especially for patients who do have HIV-related TB. Screening approaches involving patient-delivered should be evaluated for effectiveness and acceptability in a range of setting with mixed methods approaches to further explore these barriers. Importantly, linked qualitative research in this study also underscores that acceptability was generally high, however, with many patients reporting strongly positive reflections on the value of each arm. In part we identified easily remedied logistical barriers such as the need to introduce contact screening while patients are waiting to be registered, and the need to offer additional support to patients who are too ill or too poor to cope with any additional facility visits.

In conclusion, we found that a patient-delivered household TB contact screening intervention resulted in greater and more rapid uptake of TB preventive therapy. For low-resource settings struggling to implement contact tracing interventions, patient-delivered tracing could be an effective approach to increasing access to TB care and prevention services.

Supporting information

S1 Checklist. Consort checklist.

(DOCX)

S1 Dataset. Data.

(ZIP)

S1 File. COMREC accepted protocol.

(DOCX)

S1 Table. IPT initiation among under year old household contacts.

(DOCX)

Acknowledgments

The authors would like to thank the participants; the leadership and authorities of Blantyre DHO, and QECH for permission to carry out the study. We also like to thank National TB Programme for allowing this study to take place. Dr Ngwira passed away before the submission of this final manuscript. Dr Kaswaswa accept responsibility for the integrity and validity of the data collected and analysed.

Data Availability

The data that support the findings of this study are openly available as supplement 1.

Funding Statement

EL and GC were initials authors who receive the award. The grant number is 2010/859. The funder was Helse Nord TB initiative (HNTI).The funder website is www.helse-nord.no but can also be accessed on http://hnti.medcol.mw/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.2020 WHO. Global Tuberculosis Report 2020. Vol. 66, World Health Organization. 2020. WHO/CDS/TB/2019.15, 2020. Available from:http://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1.
  • 2.World Health Organization. Global tuberculosis report 2016. World Health Organization; WHO/HTM/TB/2016.13, 2016. Available from: http://apps.who.int/iris/bitstream/handle/10665/250441/9789241565394-eng.pdf;jsessionid=88D855592AB35EB6932B1229AAC976C4?sequence=1.
  • 3.World Health Organization. Global tuberculosis report 2018 [Internet]. Geneva, Switzerland: World Health Organization;2018. WHO/CDS/TB/2018.20. Available from: http://apps.who.int/iris/bitstream; 2018. [Google Scholar]
  • 4.World Health Organisation. Recommendations for investigating the contacts of persons with infectious tuberculosis in low and middle-income countries. Geneva: World Health Organisation; WHO/HTM/TB/2012.9; 2012. [cited 2018 March 27]. Available from: http://apps.who.int/iris/bitstream/10665/77741/1/9789241504492. [PubMed] [Google Scholar]
  • 5.Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 41(1):140–56. doi: 10.1183/09031936.00070812 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Underwood BR, White VL, Baker T, Law M, Moore-Gillon JC. Contact tracing and population screening for tuberculosis–who should be assessed? J Public Health Med. 25(1):59–61. doi: 10.1093/pubmed/fdg012 [DOI] [PubMed] [Google Scholar]
  • 7.Shapiro AE, Variava E, Rakgokong MH. Community-based Targeted Case Finding for Tuberculosis and HIV in Household Contacts of Patients with Tuberculosis in South Africa. Am J Respir Crit Care Med. 185(10):1110–6. doi: 10.1164/rccm.201111-1941OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.World Health Organisation. Recommendations for investigating the contacts of persons with infectious tuberculosis in low and middle income countries [Internet]. Geneva: World Health Organisation; Available from: http://apps.who.int/iris/bitstream/10665/77741/1/9789241504492_eng.pdf?ua=1. [PubMed] [Google Scholar]
  • 9.World Health Organisation. Systematic screening for active tuberculosis: Principles and recommendations. Geneva: World Health Organisation. WHO/HTM/TB/2013.04.2013. [PubMed] [Google Scholar]
  • 10.Fair E, Miller C. Hopewell P.Online Annex 4 Systematic review of the yield of tuberculosis contact investigation in low and middle income countries [homepage Internet [Internet]. Available from: http://www.who.int/tb/Systematicreviewcontact_investigation.pdf.
  • 11.Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 8(6):359–68. doi: 10.1016/S1473-3099(08)70071-9 [DOI] [PubMed] [Google Scholar]
  • 12.Rieder HL. Interventions for Tuberculosis Control and Elimination. Geneva: International Union Against Tuberculosis and Lung Disease; 2002. [Google Scholar]
  • 13.Stuckler D, Basu S, McKee M, Lurie M. Mining and risk of tuberculosis in sub-Saharan Africa. Am J Public Health. 101(3):524–30. doi: 10.2105/AJPH.2009.175646 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.World Health Organization. WHO policy on TB infection control in health-care facilities, congregate settings and households. Geneva: World Health Organisation. WHO/HTM/TB/2009.419;2009. [PubMed] [Google Scholar]
  • 15.Smit GSA, Apers L, Onate WA. Cost–effectiveness of screening for active cases of tuberculosis in Flanders. Belgium Bull World Health Organ. 95(1). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.World Health Organization. The End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: WHO; ed.2014;2. [Google Scholar]
  • 17.van’t Hoog AH, Onozaki I, Lonnroth K. Choosing algorithms for TB screening: a modelling study to compare yield, predictive value and diagnostic burden. BMC Infect Dis. 14(1). doi: 10.1186/1471-2334-14-532 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 8(15). doi: 10.1186/1471-2458-8-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Nyirenda M, Sinfield R, Haves S, Molyneux EM, Graham SM. 8. Int J Tuberc Lung Dis. 10(5):585–7. [PubMed] [Google Scholar]
  • 20.Malawi Government, Ministry of Health. National Tuberculosis Control Programme Operational Manual. Likuni: Ministry of Health; 2012. [cited 2019 March 27]. Available from:http://www.medcol.mw/globalhealth/uploads/MalawianTBguidelines2012.pdf. [Google Scholar]
  • 21.Malawi Government. Malawi Population and Housing Census Main Report Zomba, Malawi: Government Press; [Internet]. Available from: http://www.nsomalawi.mw/images/stories/data_on_line/demography/census_2008/Main%20Report/Census%20Main%20Report.pdf. [Google Scholar]
  • 22.Choko AT, Desmond N, Webb EL. The uptake and accuracy of oral kits for HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in Blantyre, Malawi. PLoS Med. 8(10). doi: 10.1371/journal.pmed.1001102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.MacPherson P, Choko AT, Webb EL. Development, and validation of a global positioning system–based “Map Book” system for categorizing cluster residency status of community members living in high-density urban slums in Blantyre, Malawi. Am J Epidemiol. 177(10):1143–7. doi: 10.1093/aje/kws376 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hayes RJ and, Bennett S. Simple sample size calculations for cluster-randomized trials. Int J Epidemiol. 28:319–26. [DOI] [PubMed] [Google Scholar]
  • 25.Richard J. Hayes, Lawrence H. Moulton. Cluster Randomised Trials: Chapman and Hall/CRC; 2009. [Google Scholar]
  • 26.Gupta S. Gupta S. Intention-to-treat concept: A review. Perspect Clin Res. 2011. Jul-Sep; 2(3): 109–112. doi: 10.4103/2229-3485.83221 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Thind D, Charalambous S, Tongman A, Churchyard G, Grant AD. An evaluation of ‘Ribolola’: a household tuberculosis contact tracing programme in North West Province, South Africa. Int J Tuberc Lung Dis. 16(12):1643–8. doi: 10.5588/ijtld.12.0074 [DOI] [PubMed] [Google Scholar]
  • 28.World Health Organisation. Guidelines for Intensified Tuberculosis Case-finding and Isoniazid Preventive Therapy for People Living with HIV in resource constrained settings Geneva,Switzerland:World Health Organisation.WHO/HTM/TB/2011.11;2011. [Internet]. Available from: http://www.who.int/tb/Systematicreviewcontact_investigation.pdf. [Google Scholar]
  • 29.World Health Organization. WHO Policy on Collaborative TB/HIV activities. Guidelines for national programmes and other stakeholders [Internet]. Geneva: World Health Organization; Available from: http://apps.who.int/iris/handle/10665/44789. [PubMed] [Google Scholar]
  • 30.Kufa T, Mabuto T, Muchiri E. Incidence of HIV-Associated Tuberculosis among Individuals Taking Combination Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS ONE. 9(11). doi: 10.1371/journal.pone.0111209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Trelle S, Shang A, Nartey L, Cassell JA, Low N. Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review. Bmj. 334(7589). doi: 10.1136/bmj.39079.460741.7C [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Kissinger P, Hogben M. Expedited Partner Treatment for Sexually Transmitted Infections: An Update. Current Infectious Disease Reports. 13(2):188–95. doi: 10.1007/s11908-010-0159-3 [DOI] [PubMed] [Google Scholar]
  • 33.Kemp JR, Mann G, Simwaka BN, Salaniponi FML, Squire SB. Can Malawi’s poor afford free tuberculosis services? Patient and household costs associated with a tuberculosis diagnosis in Lilongwe. Bull World Health Organ. 85(8):580–5. doi: 10.2471/blt.06.033167 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Nhlema B, Kemp J, Steenbergen G, Theobald G, Tang S, Squire B. The state of existing knowledge about TB and poverty. Int J Tuberc Lung Dis. 7(supp 2). [Google Scholar]
  • 35.Nhlema Simwaka B, Benson T, Salaniponi F, Theobald S, Squire S, Kemp J. Developing a socio-economic measure to monitor access to tuberculosis services in urban Lilongwe, Malawi. Int J Tuberc Lung Dis. 11(1):65–71. [PubMed] [Google Scholar]
  • 36.Nhlema B, Kemp J, Steenbergen G, Theobald S, Tang SC, Squire SB. A Systematic Analysis of TB and Poverty.Geneva. Switzerland: World Health Organisation; 2003. 4 pp. [Google Scholar]

Decision Letter 0

Richard John Lessells

6 Sep 2021

PONE-D-20-11614Effect of patient-delivered household contact tracing and prevention for tuberculosis: a household cluster-randomised trial in MalawiPLOS ONE

Dear Dr. Kaswaswa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Many thanks for submitting this manuscript to the journal. It's a really interesting trial and it's impressive how you implemented this research within the national TB program. Apologies for the length of time it's taken to get this decision to you. I was just recently asked to take on the academic editor role, it seems that the journal office had initially obtained the reviews before assigning an editor. There are three helpful reviews and I would encourage you to address the comments made by all three. I would just like to make two points where I particularly agree with the reviewers, and one additional point where it may just be me that got confused:

  1. I agree with the comment from reviewer 2 that the introduction could be substantially shortened to just capture the key background and rationale for the intervention and the study

  2. Reviewer 3 makes a good point that the time-to-event analyses appear in the Results section but not in the Methods section. If I understand correctly, these analyses were not predefined in the trial protocol or statistical analysis plan - therefore it would be helpful in the Methods section to just briefly explain that and the rationale for doing these post hoc

  3. I found the two sentences in lines 59-63 of the abstract confusing. There seemed to be two similar key results being presented here. I may have missed something but I couldn't see exactly what the difference between the two sentences was, and I couldn't tie the second sentence and the adjusted odds ratio to anything that appears in the main manuscript or tables. I would suggest restricting yourself to only presenting the two primary outcome analyses in the abstract.

Please submit your revised manuscript by Oct 21 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Richard John Lessells, BSc, MBChB, MRCP, DTM&H, DipHIVMed, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

3. Thank you for submitting your clinical trial to PLOS ONE and for providing the name of the registry and the registration number. The information in the registry entry suggests that your trial was registered after patient recruitment began. PLOS ONE strongly encourages authors to register all trials before recruiting the first participant in a study.

As per the journal’s editorial policy, please include in the Methods section of your paper:

a) your reasons for your delay in registering this study (after enrolment of participants started);

b) confirmation that all related trials are registered by stating: “The authors confirm that all ongoing and related trials for this drug/intervention are registered.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ.

5. We note that you have referenced "Malawi Government(GOM). July 2012-June 2013 Annual Tuberculosis Report (Unpublished Report).Lilongwe: National TB Programme,Malawi Government; 2013" and "Malawi Government(GOM). July 2013-June 2014 Annual Tuberculosis Report (Unpublished Report).Lilongwe: National TB Programme,Malawi Government; 2014.". which has currently not yet been accepted for publication. Please remove this from your References and amend this to state in the body of your manuscript: "Malawi Government(GOM). July 2012-June 2013 Annual Tuberculosis Report (Unpublished Report).Lilongwe: National TB Programme,Malawi Government; 2013" and "Malawi Government(GOM). July 2013-June 2014 Annual Tuberculosis Report (Unpublished Report).Lilongwe: National TB Programme,Malawi Government; 2014.". as detailed online in our guide for authors

http://journals.plos.org/plosone/s/submission-guidelines#loc-reference-style 

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a very interesting study, which is well-planned and well written-up, from the TB programme and LSHTM researchers in Malawi. It has encouraging findings, though with limited uptake (which they correctly mention needs further attention prior to further implementation/ evaluation).

The study population and context issues are very well described, as are all other parts of the paper.

The patient delivered TB contact tracing intervention ('PACTS) was a well designed, feasible and low-cost intervention in Malawi context. Indeed it should also be also be feasible in other low income, high TB prevalence settings in sub Saharan Africa.

The control is usual care (asking patients to send their household contacts to be examined at the health facility, which is difficult due to distance and cost in this setting), and was clearly described.

The outcome results are clearly described and presented. However, in the Conclusion I suggest they add into the sentance 'An alternative patient-delivered symptom screen and IPT eligibility assessment significantly increased timely IPT uptake among U5Y children, [ADD] but not a significantly increased TB diagnosis. ....

The authors could be a bit more explicit in defining the (patients' household) clusters in the study design section, as I initially wondered whether this should really be descried as a cluster RCT. So I asked my medical statistician colleague to have a look, and when he read the initial methods he also at first wondered if it is appropriate to call this a cluster RCT. That is, we both found it a little confusing initially, but now agree that it is a cluster RCT because they randomised index cases plus their households, and the outcomes are based on data from all household members.

The ethics, of obtaining data from the household members, was addressed and approval addressed that and they did ultimately obtain consent from them too.

Please note that I reviewed the paper from the perspective of experience in TB control in LMICs/Africa, and experience in conducting trials. While the statistics looked appropriate to me, I am not a statistician and I did not check in these statistical details. My statistian colleague had a look at whether it is appropriately called a cluster RCT, but he did not do the rest of a statistical review. I assume that you will have a statistician review fully.

Minor points: There were not typos or other minor problems in the script. A very small point, the authors could check and change household to households in some places.

I commend the authors for designing, conducting and writing up this intervention/ trial so expertly.

I suggest, after a satisfactory statistical review, and after addressing my minor revisions, that it be accepted for publication.

Reviewer #2: 1. Line 49 Abstract seems to contain an error: “…. proportion of all adult of TB treatment…..”

2. Line 51. What is “U5Y”? (Presume under 5 year old children).

3. Lines 80-82: something seems amiss in this sentence: “In rural South Africa, prevalence of TB in household contacts was high compared to household contacts without TB (6,075 per 100,000 versus 407 per 100,000), with most contacts with culture-confirmed TB being asymptomatic.” Do you mean “compared to people living in households without a known TB case”?

4. In my view the introduction could be substantially reduced in length. Only three paragraphs are needed:

a. Importance of contact investigation for TB control in high burden settings

b. Limitations of existing model for implementing contact investigation

c. Rationale for proposed new model that is to be evaluated here and objective the present investigation.

5. Line 140: Study design. I presume the authors mean “open label” (that is, unblinded).

6. Line 144: TB prevalence cannot have been “> 900,000 per 100,000”.

7. Line 150: needs re-wording. Suggest “Adults with pulmonary TB who registered for treatment at either site …..”

8. Line 303-305 contains an error: “apart from for sputum microbiology where index cases in the SOC arm were more likely to have microbiologically-confirmed disease than those in the SOC arm,” (The second “SOC” should be “PACT”.)

9. Line 321-322: It looks like odds ratios have been calculated with the SOC (control) group as the risk group. Is that correct? More intuitive to treat the experimental group (PACT) as the risk group.

10. Lines 367ff: Not particularly helpful to re-state the results in the first paragraph of the discussion (BTW, the value of the aOR in line 368 (0.17) is incorrect). It would be helpful to simply state the answer the study questions / objectives outline in the last paragraph of the Introduction. It seems to me that the PACT intervention did not increase case finding in household contacts. It did increase initiation, but not completion, of IPT in young children. It also increased some testing for TB.

Reviewer #3: I thought this methods utilized in this manuscript were generally good, but with some confusing parts. I also got really confused about the time-to-event model that seemed to appear out of nowhere in the discussion. Also, some editing will be needed.

1. The language is a little sloppy at times throughout. I encourage you to have this evaluated by someone for language and grammer. If you have already, whoever did it is not good enough. A couple examples:

a. (line 59-60) "PACTS arm…were significantly more likely…" Verb agreement is incorrect and, frankly I believe the subject of the sentence does not make sense.

b. (line 151) "…screened for eligible…" is incorrect.

2. (lines 270-272) Please provide a methodological citation for the method used.

3. In addition, please cite the software utilized for these analyses (if any) as well as the level of significance.

4. (line 336) Instead of "not significantly likely to complete", I suggest saying, "not at significantly higher odds of completing".

5. (lines 349-350) This is too unstable to report, likely because of the zero count. This is tough in the context of a mixed model. Ideally one would run an exact method here, but as far as I know, exact methods will not allow you to include random effects or anything to account for the clustering. I'm guessing that's the way to go. The CI will be so wide with or without random effects that I would just run an exact method and note that it was run this way.

6. (lines 367-373) I was confused about which model is which here since all outcomes are individual-level. Maybe you can tie these into what is mentioned from the primary and secondary outcomes sections.

7. (line 370) There was no time-to-event analysis mentioned in the methods. If these were analyses run for this manuscript, please include them in the methods and probably a table is needed. If these are from a different manuscript, please cite that manuscript here.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: John Walley, Professor of International Public Health, Nuffield Centre for International Health and Development, University of Leeds, UK.

Reviewer #2: Yes: Guy B Marks

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Sep 8;17(9):e0269219. doi: 10.1371/journal.pone.0269219.r002

Author response to Decision Letter 0


9 Dec 2021

We have addressed the issues raised by the reviewer in the communication letter under the "Responses to reviewer's" file

Attachment

Submitted filename: _Response to Reviewers_ 08122021.docx

Decision Letter 1

Richard John Lessells

2 Mar 2022

PONE-D-20-11614R1Effect of patient-delivered household contact tracing and prevention for tuberculosis: a household cluster-randomised trial in MalawiPLOS ONE

Dear Dr. Kaswaswa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. There are just a few remaining minor points for you to address from the reviewers. If you can please do your best to attend to these in a revision then hopefully we can move to a final acceptance.  Please submit your revised manuscript by Apr 16 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Richard John Lessells, BSc, MBChB, MRCP, DTM&H, DipHIVMed, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I have found it difficult to review the revisions made, as there is no file with track changes or other details of the revisions.

Also I'm constrained doing the review as I'm currently on extended leave overseas and working from a tablet not computer in a guest house.

I still feel this paper should be published, but with minor revisions, as I've noticed another problem. The secondary outcome descriptions, i and iv (from line 208) are not clearly diffierent Furthermore the presentation of these secondary outcomes in the results text and tables 2 and 3 don't seem to match in their order and description. Please review and edit for clarifty and consistency.

Reviewer #2: Most of the comments that I made previously have been adequately addressed. There are some matters still to be addressed.

1. Some improved clarity is still needed. Suggestion for the Abstract as follows. Line 42-44: Would be better written as “Between May and December, 2014, we randomised patients with TB who consented to participate in the trial to either standard of care (SOC) or intervention (PACTS) arms. Participants randomised to PACTS received ….”. Line 47: “Patients randomised to SOC were managed in accordance with national guidelines, that is, they received verbal instruction …..”. Line 50-52: “The primary outcome was the proportion of adult contacts receiving treatment for TB within 3 months of randomisation. Secondary outcomes were the proportions of child contacts under age 5 years (U5Y) who were commenced on, and completed, TPT. Data were analysed by logistic regression with random effects to adjust for household clustering.”.

2. Introduction is much improved.

3. It would be helpful to cite the number of people who met the eligibility criteria (464) in the results text (line 267).

4. I note the response in relation to using the intervention group (PACTS) as the reference group for odds ratios. I do not agree. In essence, the reference group should be the control group. A “risk” or odds ratio that is less than one is readily interpreted as indicating that the intervention is protective, which is what you are seeking to achieve. If you insist on using the intervention group as the reference for the expression of odds ratios, you should at least make this clear in the methods and in the results and tables when you present the results. Otherwise, most people will misinterpret them.

5. In table 2 you need a footnote to show what covariates adjusted for.

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Guy B Marks

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 2

Richard John Lessells

18 May 2022

Effect of patient-delivered household contact tracing and prevention for tuberculosis: a household cluster-randomised trial in Malawi

PONE-D-20-11614R2

Dear Dr. Kaswaswa,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Richard John Lessells, BSc, MBChB, MRCP, DTM&H, DipHIVMed, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Richard John Lessells

16 Aug 2022

PONE-D-20-11614R2

Effect of patient-delivered household contact tracing and prevention for tuberculosis: a household cluster-randomised trial in Malawi

Dear Dr. Kaswaswa:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Richard John Lessells

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. Consort checklist.

    (DOCX)

    S1 Dataset. Data.

    (ZIP)

    S1 File. COMREC accepted protocol.

    (DOCX)

    S1 Table. IPT initiation among under year old household contacts.

    (DOCX)

    Attachment

    Submitted filename: _Response to Reviewers_ 08122021.docx

    Attachment

    Submitted filename: _Response to Reviewers_ 16032022.docx

    Data Availability Statement

    The data that support the findings of this study are openly available as supplement 1.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES